Harvard Bioscience (HBIO) Liabilities from Discontinued Operations (2017)
Harvard Bioscience (HBIO) posted quarterly Liabilities from Discontinued Operations of 1857000.0 for Q4 2017.
Harvard Bioscience (HBIO) Liabilities from Discontinued Operations (2017) Analysis & Trends
Harvard Bioscience (HBIO) has reported Liabilities from Discontinued Operations for 1 consecutive years, with 1857000.0 the latest figure, recorded in Q4 2017.
- In Q4 2017, Liabilities from Discontinued Operations changed N/A year-over-year to 1857000.0; the TTM figure through Dec 2017 stood at 1857000.0 (changed N/A YoY), while the FY2017 annual figure was 1857000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations steadied at 1857000.0 in Q4 2017 per HBIO's latest filing.
- Across five years, Liabilities from Discontinued Operations topped out at 1857000.0 in Q4 2017 and bottomed at 1857000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn |
| 10 | Harvard Bioscience | 33.45 Mn | 26.94 Mn | 12.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 1.86 Mn |
| Dec 31, 2017 | 1.86 Mn |